Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The PA criteria require BMI 30 or higher (or 27 with a comorbidity such as type 2 diabetes, hypertension, dyslipidemia, OSA, or CVD), documentation of a 6-month structured weight management program, prescriber attestation that lifestyle change alone has failed, and age 18 or older
Treatment should be discontinued if patients have not lost at least 5% of their initial body weight after 12 weeks at the maintenance dose
MARCH 2026 A real-world clinical study found that patients who discontinued GLP-1 medications experienced meaningful weight regain, underscoring the need for sustained behavioral and nutritional support for long-term results
Vegan, third-party tested, highly responsive customer support, 45-day guarantee
However, 'moderate' becomes meaningless if you're drinking on an empty stomach or without eating alongside your alcohol, so solid food intake is essential
doi: 10.1186/s12933-022-01474-z Summary Keywords glucagon-like peptide-1, glucagon-like peptide-1 receptor agonist, cardiovascular diseases, major adverse cardiovascular events, diabetes mellitus Citation Ferhatbegovi L, Mri D and Maci-Dankovi A (2023) The benefits of GLP1 receptors in cardiovascular diseases
